Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
Damora Therapeutics, Inc. (NASDAQ: DMRA)
DMRA Stock Predictions and Ratings
WSX Rating:
BUY
WSX Forecast (1yr):
7.90%
Analyst Rating:
BUY
Analyst Forecast (1yr):
68.70%
DMRA Stock Analysis
DMRA
PE Ratio:
4.2
DMRA
PEG Ratio:
Not Available
DMRA
Forward EPS Growth (12 month):
0.00%
DMRA
PS Ratio:
DMRA
PSG Ratio:
Not Available
DMRA
Forward Revenue Growth (12 month):
0.00%
DMRA Articles
No data was found